ClinicalTrials.govpublic full text
A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis
lupus nephritis, systemic lupus erythematosus, sle - systemic lupus erythematosus, lupus nephritis - who class iii, lupus nephritis - who class iv, ft819, fate therapeutics, allogeneic car t, cd19 - targeted therapy, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 1008529
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.